Boston Pharmaceuticals is dedicated to developing advanced therapies specifically targeting serious liver diseases. Their pipeline includes innovative treatments such as Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue designed for metabolic dysfunction-associated steatohepatitis (MASH). This investigational drug is currently undergoing Phase 2 clinical trials and has shown promise in improving liver health markers and metabolic profiles in patients. Efimosfermin is engineered as a fusion protein, enhancing its systemic half-life and specificity for FGF21 receptors, which may contribute to its therapeutic efficacy in managing MASH, a condition that is increasingly prevalent due to rising obesity rates.

In addition to their cardiometabolic focus, Boston Pharmaceuticals is also advancing oncology treatments, notably BOS-342, a bispecific antibody targeting Glypican-3 (GPC3) and 4-1BB (CD137) for hepatocellular carcinoma (HCC). This first-in-class therapy is designed to selectively bind to GPC3-expressing tumors, activating immune responses to combat cancer progression. Currently in clinical evaluation, BOS-342 represents a significant step forward in the treatment of HCC, which is the most common form of liver cancer. The company’s commitment to evidence-based decision-making and strategic partnerships with leading biotechnology firms underscores their goal of delivering impactful therapies for patients suffering from serious liver conditions.

United States

Transforming the right molecules into the best medicines™

Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for our diverse pipeline.

Boston Pharmaceuticals

Company Details